Cholecalciferol

SIGMA/C9756 - ≥98% (HPLC)

Synonym: (+)-Vitamin D₃; 7-Dehydrocholesterol activated; Activated 7-dehydrocholesterol; Calciol

CAS Number: 67-97-0
Empirical Formula (Hill Notation): C₂₇H₄₄O
Molecular Weight: 384.64
EC Number: 200-673-2
MDL Number: MFCD00078131
Linear Formula: C₂₇H₄₄O
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-C9756-1G	1 g	$64.20 1/EA	Add To Favorites
45-C9756-5G	5 g	$246.00 1/EA	Add To Favorites

This picture is provided solely for illustration purposes. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material. This image depicts SKU: C9756-1G

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
biological source	synthetic (organic)
color	white to off-white
form	powder
InChI	1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
InChI key	QYSXJUFSXHHAJI-YRZJJWOYSA-N
mp	83-86 °C (lit.)
Quality Level	200
SMILES string	CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=CC=C(C[C@@H](O)CC3)/C3=C
storage temp.	2-8°C
technique(s)	HPLC: suitable

Application:	Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation.: This study delves into the significant roles of cholecalciferol in modulating the renal-bone axis, inflammatory responses, and iron metabolism in elderly patients with renal impairment. Through vitamin D supplementation, researchers observed pivotal changes that could guide future therapeutic strategies (Christodoulou M et al., 2024 ). Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study.: This clinical trial assesses the efficacy of cholecalciferol in improving the health outcomes of patients with multiple sclerosis. The use of cholecalciferol potentially enhances neurological function and reduces disease progression, illustrating its vital role in neurodegenerative disease management (Maghbooli Z et al., 2024 ). Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway.: This pivotal research links cholecalciferol to the reduction of COVID-19 severity through its regulatory effects on the NLRP3 inflammasome pathway. The findings underscore the potential of vitamin D as a modulatory agent in the immune response against viral infections (Khalil B et al., 2024 ). Effects of Vitamin D Supplementation on Central Hemodynamic Parameters and Autonomic Nervous System in Obese or Overweight Individuals.: This randomized controlled trial explores how cholecalciferol supplementation can affect cardiovascular and autonomic functions in obese or overweight patients, providing insights into its benefits beyond bone health and into cardiovascular regulation (Faria ACC et al., 2024 ).
Biochem/physiol Actions:	Deficiency of vitamin D is often observed in chronic kidney disease.
Biochem/physiol Actions:	Vitamin D acts through a receptor that is a member of the ligand-dependent transcription factor superfamily. Modulates the proliferation and differentiation of both normal and cancer cells. Has antiproliferative and antimetastatic effects on breast, colon, and prostate cancer cells. Activated vitamin D receptors in intestine and bone maintain calcium absorbance and homeostasis.
Biochem/physiol Actions:	Vitamin D acts through a receptor that modulates the proliferation and differentiation of both normal and cancer cells.
General description:	Cholecalciferol acts as a hormone precursor since it requires two stages of metabolism: first to 25-hydroxycholecalciferol; then to 1α, 25-dihydroxycholecalciferol. One unit (U.S.P. or international) is defined as the activity of 0.025 μg of vitamin D3 contained in the USP vitamin D reference standard.
General description:	Cholecalciferol is sourced either through the diet or exposing skin to ultraviolet rays. Oral administration of vitamin D₃ is readily absorbed and is stored in adipose tissue.
Packaging:	1, 5 g in glass bottle
Preparation Note:	Cholecalciferol C9756 is packaged under argon gas. If it is stored unopened at 2-8°C and protected from light, this product should be stable for a minimum of three years. Unused portions should be stored under nitrogen or argon gas. Deterioration is negligible after storage of one year in amber-evaculated ampules at refrigerator temperatures. It is oxidized and inactivated by moist air within a few days.

Symbol	GHS06,GHS08
Signal word	Danger
Hazard statements	H300 + H310 + H330 - H372
Precautionary statements	P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314
Hazard Codes	T+
Risk Statements	24/25-26-48/25
Safety Statements	28-36/37-45
RIDADR	UN 2811 6.1 / PGII
WGK Germany	WGK 2
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
mp	83-86 °C (lit.)
Storage Temp.	2-8°C
UNSPSC	12352209

To Order From a Quote